Srs Capital Advisors, Inc. Biotechnology

Srs Capital Advisors, Inc.

$1.07 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NUVB Nuvation Bio Inc.	$563M	$0 0.0% of portfolio	234	Q2 2024 New
IKNA Ikena Oncology, Inc.	$60.9M	$0 0.0% of portfolio	299	Q2 2024 New
KURA Kura Oncology, Inc.	$1.07B	$0 0.0% of portfolio	26	Q2 2024 New
ADPT Adaptive Biotechnologies Corp	$640M	$0 0.0% of portfolio	97	Q2 2024 New
TBPH Theravance Biopharma, Inc.	$662M	$0 0.0% of portfolio	57	Q2 2024 New
KPTI Karyopharm Therapeutics Inc.	$63M	$0 0.0% of portfolio	538	Q2 2024 New
AURA Aura Biosciences, Inc.	$268M	$0 0.0% of portfolio	49	Q2 2024 New
ALEC Alector, Inc.	$318M	$0 0.0% of portfolio	84	Q2 2024 New
VOR Vor Biopharma Inc.	$29.7M	$0 0.0% of portfolio	528	Q2 2024 New
ALVR Allovir, Inc.	$54M	$0 0.0% of portfolio	451	Q2 2024 New
FATE Fate Therapeutics Inc	$211M	$0 0.0% of portfolio	102	Q2 2024 New
XFOR X4 Pharmaceuticals, Inc	$24.7M	$0 0.0% of portfolio	503	Q2 2024 New
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	22	Q2 2024 New
VKTX Viking Therapeutics, Inc.	$3.77B	$0 0.0% of portfolio	5	Q2 2024 New
PHAT Phathom Pharmaceuticals, Inc.	$348M	$0 0.0% of portfolio	17	Q2 2024 New
MGTX Meira G Tx Holdings PLC	$274M	$0 0.0% of portfolio	73	Q2 2024 New
COGT Cogent Biosciences, Inc.	$591M	$0 0.0% of portfolio	28	Q2 2024 New
RPHM Reneo Pharmaceuticals, Inc.	$41.1M	$0 0.0% of portfolio	171	Q2 2024 New
SNDX Syndax Pharmaceuticals Inc	$892M	$0 0.0% of portfolio	14	Q3 2024 New
CRMD Cor Medix Inc.	$450M	$0 0.0% of portfolio	31	Q2 2024 New
ETNB 89bio, Inc.	$370M	$0 0.0% of portfolio	33	Q2 2024 New
AVTE Aerovate Therapeutics, Inc.	$61.9M	$0 0.0% of portfolio	117	Q2 2024 New
RGNX Regenxbio Inc.	$413M	$0 0.0% of portfolio	23	Q2 2024 New
ATNM Actinium Pharmaceuticals, Inc.	$35.8M	$0 0.0% of portfolio	126	Q2 2024 New
TNYA Tenaya Therapeutics, Inc.	$85.2M	$0 0.0% of portfolio	105	Q2 2024 New
RXRX Recursion Pharmaceuticals, Inc.	$1.13B	$0 0.0% of portfolio	29	Q3 2024 Reduced 91.83%
ZNTL Zentalis Pharmaceuticals, Inc.	$170M	$0 0.0% of portfolio	50	Q2 2024 New
SEER Seer, Inc.	$134M	$0 0.0% of portfolio	90	Q2 2024 New
TYRA Tyra Biosciences, Inc.	$649M	$0 0.0% of portfolio	7	Q2 2024 New
CUE Cue Biopharma, Inc.	$39.3M	$0 0.0% of portfolio	215	Q2 2024 New
LYEL Lyell Immunopharma, Inc.	$275M	$0 0.0% of portfolio	95	Q2 2024 New
SGMO Sangamo Therapeutics, Inc	$307M	$0 0.0% of portfolio	142	Q2 2024 New
XENE Xenon Pharmaceuticals Inc.	$2.42B	$0 0.0% of portfolio	3	Q2 2024 New
CGEM Cullinan Oncology, Inc.	$598M	$0 0.0% of portfolio	7	Q2 2024 New
DAWN Day One Biopharmaceuticals, Inc.	$993M	$0 0.0% of portfolio	8	Q2 2024 New
PSTX Poseida Therapeutics, Inc.	$229M	$0 0.0% of portfolio	38	Q2 2024 New
ALLK Allakos Inc.	$90.7M	$0 0.0% of portfolio	159	Q2 2024 New
EYEN Eyenovia, Inc.	$3.76M	$0 0.0% of portfolio	196	Q2 2024 New
GBIO Generation Bio Co.	$84.4M	$0 0.0% of portfolio	38	Q2 2024 New
OMGA Omega Therapeutics, Inc.	$36.8M	$0 0.0% of portfolio	54	Q2 2024 New
PRLD Prelude Therapeutics Inc	$34.2M	$0 0.0% of portfolio	19	Q2 2024 New
PLX Protalix Bio Therapeutics, Inc.	$82.1M	$0 0.0% of portfolio	39	Q2 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.